Skip to Main Content
Table 4

C26/IL-12 Tumor–associated Vessels Detected by Immunocytochemistry

CD31CD34αvβ3
BALB/c      5 ± 4*  4 ± 4  ND 
 + mAb to CD8  41 ± 11  33 ± 8  5 ± 2 (12%) 
 + mAb to CD4  3 ± 2  5 ± 2  ND 
GKO  20 ± 6  21 ± 15  <1 
 + mAb to CD8  42 ± 13  31 ± 3  <1 
 + mAb to CD4  69 ± 26  51 ± 18  9 ± 2 (13%) 
C26 in BALB/c  71 ± 10  53 ± 15  9 ± 3 (13%) 
C26 in GKO  55 ± 16  31 ± 2  8 ± 2 (14%) 
CD31CD34αvβ3
BALB/c      5 ± 4*  4 ± 4  ND 
 + mAb to CD8  41 ± 11  33 ± 8  5 ± 2 (12%) 
 + mAb to CD4  3 ± 2  5 ± 2  ND 
GKO  20 ± 6  21 ± 15  <1 
 + mAb to CD8  42 ± 13  31 ± 3  <1 
 + mAb to CD4  69 ± 26  51 ± 18  9 ± 2 (13%) 
C26 in BALB/c  71 ± 10  53 ± 15  9 ± 3 (13%) 
C26 in GKO  55 ± 16  31 ± 2  8 ± 2 (14%) 

Frozen sections were stained with mAb by immunocytochemistry (PAP method) except for αvβ3, which required a fluorescein-conjugated Ab followed by antifluorescein for detection by peroxidase. Tumors were analyzed at day 10.  

*

 Mean number of cells/mm2 ± SD positive for immunostaining.  

 Percentage of CD31+ cells that were αvβ3+.  

Close Modal

or Create an Account

Close Modal
Close Modal